A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...